Surf Wiki
Save to docs
general/analgesics

From Surf Wiki (app.surf) — the open knowledge base

Indantadol

Chemical compound

Chemical compound

| elimination_half-life =

Indantadol (developmental code names CHF-3381, V-3381) is a drug of the 2-aminoindane family which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.

References

References

  1. (June 2001). "Preclinical evaluation of CHF3381 as a novel antiepileptic agent". Neuropharmacology.
  2. (September 2001). "Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms". Pharmacology Biochemistry and Behavior.
  3. (November 2002). "Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist". NeuroReport.
  4. (August 2003). "Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain". The Journal of Pharmacology and Experimental Therapeutics.
  5. (2004). "CHF 3381". Drugs in R&D.
  6. (September 2007). "Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain". IDrugs: The Investigational Drugs Journal.
  7. "IN-STEP Phase IIb study results".
  8. "Vernalis initiates Pilot Study of V3381 in patients with chronic cough".
  9. (August 2006). "CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model". The Journal of Pain.
  10. (August 2003). "Mechanisms of action of CHF3381 in the forebrain". British Journal of Pharmacology.
  11. "V3381CC".
  12. "Vernalis completes recruitment in V3381 Phase II IN-STEP study for neuropathic pain".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

analgesics anticonvulsants antitussives monoamine-oxidase-inhibitors nmda-receptor-antagonists 2-aminoindanes acetamides
Want to explore this topic further?

Ask Mako anything about Indantadol — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report